Abstract: A method of monitoring and managing performance of an artificial neural network model for an air interface may comprise: receiving, by a network (NW) including a communication node performing a function of monitoring and managing performance of an artificial neural network model, a performance metric of the artificial neural network model from a user equipment (UE); and controlling, by the communication node, activation or deactivation of the artificial neural network model according to the performance metric, wherein the artificial neural network model is activated to improve a main performance metric of a mobile communication system including the communication node and the UE connected through an air interface.

Abstract: A method of a terminal may comprise: receiving a first message including state information of a base station from the base station; identifying preliminary inactive state information included in the first message when the state information of the base station indicates a preliminary inactive state; and performing a cell selection based on the preliminary inactive state information.

Abstract: A method of a terminal may comprise: receiving a reference signal from a base station; generating channel information based on the reference signal; generating wavelet-transformed channel information by applying wavelet transform to the channel information; generating compressed channel information by compressing the wavelet-transformed channel information; and transmitting the compressed channel information to the base station.

Abstract: A holographic optical element and a method for producing the same are disclosed herein. In some embodiments, a method includes illuminating a first surface of a photopolymer resin layer, where the photopolymer resin layer comprises a photopolymer resin, illuminating a second surface of the photopolymer resin layer through a retardation layer disposed in the second surface, wherein the second surface is opposite the first surface, and recording an interference pattern in the photopolymer resin layer, wherein the interference pattern is created by interference between the first parallel laser beam and the second parallel laser beam. The holographic optical element is produced using a retardation layer to prevent an unwanted interference pattern from being formed in the process of recording an interference pattern in a photopolymer resin layer.

Abstract: Disclosed is a head mounted display which can secure an eye motion box having a certain level by implementing an image using a holographic optical element, the eye motion box being an area where a wearer can visually recognize the image, extend the field of view (FOV) of the wearer by disposing a lens (imaging lens) on an optical path between a display source and the holographic optical element, and secure an eye motion box having a certain level and extend the field of view (FOV) of the wearer by adjusting the positions of the display source and the lens.

Abstract: A head mounted display is disclosed herein. In some embodiments, a head mounted display includes a lens unit configured to be disposed in front of an eye of a wearer; an holographic optical element disposed on an eye side surface or a surface opposite the eye side surface of the lens unit; and an image display unit configured to be disposed on a lateral side of the eye of the wearer and configured to output image display light. The image display unit includes at least one of a liquid crystal display panel or an organic light emitting display panel to output the image display light toward the holographic optical element, and the holographic optical element diffracts the image display light and reflects the diffracted image display light toward the eye of the wearer.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract: The present invention provides a compound of formula (I) or a prodrug thereof useful for treating or preventing irritable bowel syndrome, and a composition comprising the compound as an active ingredient. Also, the present invention provides a method for treating or preventing irritable bowel syndrome, which comprises administrating a therapeutically or prophylactically effective amount of the compound or the composition to a subject in need of treating or preventing irritable bowel syndrome.

Abstract: Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11?-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11?-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11?-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

Abstract: The present invention relates to a composition or a method for treating or preventing irritable bowel syndrome. The present invention uses Atractylodes japonica rhizome extract, preferably the ethanol water solution extract of Atractylodes japonica rhizome, more preferably the 35-65 v/v % ethanol water solution extract of Atractylodes japonica rhizome for treating or preventing irritable bowel syndrome. Atractylodes japonica rhizome extract shows a surprising effect in suppressing visceral hypersensitivity or improving defecation abnormality caused by stress or bowel irritability.